Navigation Links
Caliper Life Sciences and DiscoveRx Collaborate to Offer Solutions for Cell-Based GPCR Profiling and Lead Optimization
Date:5/5/2008

- Nearly 40% of Drugs on the Market and 30% of Active R&D Programs Target

GPCRs -

HOPKINTON, Mass., May 5 /PRNewswire-FirstCall/ -- Caliper Life Sciences, Inc. (Nasdaq: CALP) today announced a collaboration with DiscoveRx Corporation that enables functional cell-based G protein-coupled receptor (GPCR) assays from DiscoveRx to be performed on Caliper's LabChip(R) platforms. The combined offering bundles Caliper LabChip systems with DiscoveRx's cellular assays, including PathHunter(TM) Beta Arrestin and cAMP Hunter(TM), to assist pharmaceutical and biotechnology researchers in more efficiently discovering GPCR drugs.

"This collaboration will expand the capability of Caliper's LabChip technology into the dynamic GPCR drug discovery market, an opportunity with substantial potential due to the importance of GPCR drugs and the number of active R&D programs in neuroscience, cardiovascular, inflammation and other disease areas. Through our collaboration with DiscoveRx, we have expanded our offerings to provide researchers with the ability to prosecute GPCR targets in a functional cellular assay for lead optimization and profiling," said Kevin Hrusovsky, CEO of Caliper Life Sciences. "Caliper's LabChip platform has become the new standard for kinase assays and we have broadened the platform to enable testing of phosphodiesterases, histone deacetylases (including sirtuins) proteases, phophatases and lipid modifying enzymes. The addition of cellular GPCR assays, which are a critical linkage in translational research, expands Caliper's in vitro-in vivo bridge and should provide our customers with enhanced ability to make more informed decisions that ultimately lead to safer and more effective drugs."

Caliper's LabChip instruments -- the LabChip 3000 and LabChip EZ Reader(R) series -- which have been adopted by 17 of the top 20 pharmaceutical and biotechnology companies, utilize proprietary microfluidic separation and direct detection of both substrates and products to generate high quality results. This robust, easy-to-use platform, combined with DiscoveRx's innovative Beta-Galactosidase Enzyme Fragment Complementation (EFC) approach for cellular GPCR assays, should provide researchers with the ability to perform more clinically relevant cellular-based assays.

"PathHunter(TM) Beta-Arrestin assays, HitHunter(TM) cAMP detection and now cAMP Hunter(TM) cell lines are all being successfully adopted by leading pharmaceutical companies in their GPCR screening campaigns. Our partnership with Caliper enables the use of these highly successful cell-based GPCR assays on Caliper's microfluidic technology platform to provide a powerful and comprehensive suite of solutions for Caliper's EZ Reader and kinase profiling customers," said Pyare Khanna, CEO of DiscoveRx Corporation. "Together, we are meeting the demand for GPCR and Kinase lead optimization and profiling."

About DiscoveRx Corporation

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with an additional office in Birmingham, England. The company pioneered the use of Beta-Galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, Kinases and other major drug target classes, and many of their innovative products have been widely adopted in pharmaceutical and biotech drug screening laboratories worldwide. For more information on DiscoveRx products, please visit http://www.discoverx.com

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation & liquid handling, optical imaging technologies, and discovery & development outsourcing solutions. For more information please visit http://www.caliperLS.com.

Caliper, LabChip, and EZ Reader are registered trademarks of Caliper Life Sciences, Inc.

DiscoveRx is a registered trademark, and PathHunter(TM), HitHunter(TM) and cAMP Hunter(TM) are trademarks, of DiscoveRx Corporation.


'/>"/>
SOURCE Caliper Life Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Caliper Life Sciences Reports West Coast Consolidation of Operations
2. Increased Light Leads to Early Detection: Caliper Life Sciences Introduces Bioware(R) Ultra Cancer Cell Lines
3. Caliper Life Sciences Forms Alliance With Horizon Discovery to Provide Enhanced Solutions for Cancer Research Based on Isogenic Cell Lines
4. Caliper Life Sciences Announces Date and Location of its 2008 Annual Meeting of Stockholders
5. Caliper Life Sciences Appoints Peter F. McAree Senior Vice President and Chief Financial Officer
6. Caliper Life Sciences to Present at Lehman Brothers Global Healthcare Conference
7. Caliper Life Sciences to Present at Cowen and Company 28th Annual Health Care Conference
8. Caliper Life Sciences Fourth Quarter 2007 Financial Results Conference Call Notice
9. Caliper Life Sciences to Present at Deutsche Bank 2008 Small and Mid Cap Growth Conference
10. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
11. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... 29, 2016 According to ... Research "Separation Systems for Commercial Biotechnology Market - ... Forecast 2015 - 2023", the separation systems for ... Mn in 2014 and is projected to expand ... 2023 to reach US$ 19,227.8 Mn in 2023. ...
(Date:4/28/2016)... , April 28, 2016 The ... and Brayton Cryocoolers), Service (Technical Support, Product Repairs & ... - Global Forecast to 2022", published by MarketsandMarkets, the ... Billion by 2022, at a CAGR of 7.29% between ... data Tables and 94 Figures spread through 159 Pages ...
(Date:4/28/2016)... ... April 28, 2016 , ... Morris Midwest ( http://www.morrismidwest.com ), ... manufacturers at its Maple Grove, Minnesota technical center, May 11-12. The event ... Almost 20 leading suppliers of tooling, accessories, software and other related technology ...
(Date:4/27/2016)... Columbia , April 27, 2016 ... "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... Anschluss an ihre Pressemitteilung vom 13. August 2015 ... hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten auf ... Kanadische Dollar zu bringen. Davon wurden 157.900.000 Einheiten ...
Breaking Biology Technology:
(Date:5/3/2016)... VILNIUS, Lithuania , May 3, 2016 /PRNewswire/ ... today released the MegaMatcher Automated Biometric Identification ... deployment of large-scale multi-biometric projects. MegaMatcher ABIS can ... and accuracy using any combination of fingerprint, face ... of MegaMatcher SDK and MegaMatcher ...
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted to ... of 2015 The gross margin was 49% (27) ... operating margin was 40% (-13) Earnings per share rose ... was SEK 249.9 M (21.2) , Outlook   ... The operating margin for 2016 is estimated to exceed ...
Breaking Biology News(10 mins):